BSEM-001

**BSEM-001** is an investigational **biologic perinatal tissue-derived therapy** being developed by **BioStem Technologies** as a potential treatment for **acute respiratory distress syndrome**. Publicly available pipeline descriptions identify it specifically as an **amniotic fluid therapy** and place it in BioStem's regenerative medicine portfolio focused on placental and perinatal tissue products. Detailed composition, molecular targets, route, dosage form, and mechanism of action have not been clearly disclosed in the accessible sources, but the therapeutic rationale appears to be based on the anti-inflammatory and regenerative properties commonly attributed to perinatal tissue-derived biologics for severe pulmonary injury.

Other names

amniotic fluid therapy